Barclays PLC Autolus Therapeutics PLC Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 15,800 shares of AUTL stock, worth $25,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,800

Previous 15,800 -0.0%

Holding current value

$25,912

Previous $36,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$1.14 - $2.4 $834 - $1,756	732 Added 4.86%	15,800 $36,000
Q1 2025 May 15, 2025	BUY	$1.55 - $2.68 $4,973 - $8,600	3,209 Added 27.06%	15,068 $23,000
Q4 2024 Feb 13, 2025	BUY	$2.18 - $4.8 $23,687 - $52,156	10,866 Added 1094.26%	11,859 $28,000
Q3 2024 Nov 15, 2024	BUY	$3.38 - $4.69 $3,356 - $4,657	993 New	993 $4,000
Q2 2022 Aug 12, 2022	SELL	$2.04 - $4.68 $30,750 - $70,546	-15,074 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.52 - $5.46 $53,060 - $82,304	15,074 New	15,074 $63,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $20 - $28	-4 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$5.32 - $7.37 $271 - $375	-51 Reduced 92.73%	4 $0
Q2 2021 Aug 13, 2021	SELL	$4.78 - $7.96 $167 - $278	-35 Reduced 38.89%	55 $0
Q1 2021 May 13, 2021	SELL	$5.49 - $9.36 $318 - $542	-58 Reduced 39.19%	90 $1,000
Q4 2020 Feb 11, 2021	BUY	$8.13 - $12.79 $813 - $1,279	100 Added 208.33%	148 $1,000
Q2 2020 Aug 12, 2020	BUY	$5.38 - $16.14 $258 - $774	48 New	48 $1,000
Q1 2020 May 13, 2020	SELL	$4.2 - $13.0 $75 - $234	-18 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$11.13 - $16.28 $35,360 - $51,721	-3,177 Reduced 99.44%	18 $0
Q3 2019 Nov 14, 2019	BUY	$9.79 - $16.72 $30,838 - $52,668	3,150 Added 7000.0%	3,195 $40,000
Q2 2019 Aug 14, 2019	SELL	$15.1 - $31.25 $21,970 - $45,468	-1,455 Reduced 97.0%	45 $1,000
Q1 2019 May 15, 2019	SELL	$24.38 - $34.71 $47,809 - $68,066	-1,961 Reduced 56.66%	1,500 $47,000
Q4 2018 Feb 14, 2019	BUY	$24.21 - $48.01 $83,790 - $166,162	3,461 New	3,461 $113,000
Q3 2018 Nov 14, 2018	SELL	$20.86 - $33.33 $126,244 - $201,713	-6,052 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$25.0 - $27.75 $151,300 - $167,943	6,052 New	6,052 $162,000

Others Institutions Holding AUTL

# of Institutions

100

Shares Held

164M

Call Options Held

Put Options Held

39.3K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $149M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account